Emmanuel PETIOT, CEO
Education: EDHEC Business School, École Centrale Paris
Career: Emmanuel PETIOT joined Air Liquide where he held various marketing and sales functions (1996-2000). He then joined Dow Chemical (2000-2004) before joining Novozymes, Danish industrial biotechnology company and world leader in enzymes and microorganisms. In nine years (2004-2012) he had several executive positions in marketing, sales and development of industrial partnerships in Europe, the USA and Asia. He was CEO of the French subsidiary of Novozymes that provided operational support group for all of Europe. Before joining DEINOVE, he was Commercial Director of Novozymes North America Inc., the main global market for enzymes.
Dominique LE BELLER, CEO of DEINOBIOTICS
Education: Biological Engineer with a Doctorate in Microbiology, Bioconversions and Enzymology (Université de Technologie de Compiègne).
Career: Dominique LE BELLER spent his all career in the Pharma industry (HOESCHST-MARION-ROUSSEL, AVENTIS) researching on ati-infective agents and notably contributed to the development of 3 antibiotics: Ketek®, NXL 201 and NXL 104. With the Institut Pasteur, he also played an active role in the creation and implementation of the "Infectology" subject at the Pole MEDICEN, and launched the first "chemical library" project. In 2004, Dominique LE BELLER co-founded Novexel and directed projects, operations and human resources at this start-up specialized in the development of anti-infective agents until it was bought by Astra Zeneca for nearly $500 million in 2010.
Marie BEZENGER, Director of Operations
Education: Food sciences graduate (Polytech Montpellier) and holds a PhD in Biochemistry, Cell & Molecular Biology (University of Montpellier).
Career:Marie Bézenger spent over 20 years within the Chr. Hansen group, one of the world's leading producers of natural ingredients – natural colors, enzymes, probiotics, etc. - for food and health. She has held successively the positions of Head of the Dairy Cultures Department, Innovation Director of Dairy France in the Cultures & Enzymes Division, and also Major Accounts Technical Director. Before joining DEINOVE, she was Director of Operations at Fermentalg.
Julien COSTE, Director of Finance & Administration
Education: ESC Grenoble business school, Paris-Dauphine University.
Career: Director of Finance and Administration of Neuro3d, a biotechnology start-up based in Mulhouse. More recently, he held the same responsibilities for the French part of Publicis Healthcare Communications Group (PHCG), a division of Publicis. He has extensive experience in management, having worked both for young innovative companies and global corporations and listed companies.
Sébastien ENAULT, Head of Business Développement
Education: Engineer in Pharmacology & Biotechnologies (Polytechnic School of Nice Sophia-Antipolis, France), CEGOS training courses in Business Development.
Career: Before joining DEINOVE, Sébastien Enault was in charge of the Business Development of Eligo Bioscience, a start-up hosted at the Institut Pasteur in Paris, which develops a new generation of ultra-targeted antibiotics. Préviously, Sébastien Enault has structured and managed the Business Development of MedinCell, a biopharmaceutical company specializing in long-acting drug delivery. In ten years, he has contributed to the rapid growth of the company, including the signing of partnerships and agreements with major pharmaceutical companies. Prior to his experience in the private sector, Sébastien conducted research in pharmacology in the fields of infectious diseases, oncology and neurology at the Faculty of Pharmacy in Marseille, then at Cancer Research UK, and at Harvard Medical School.
Georges GAUDRIAULT, Director of Research & Development
Education: University Of Nice - Sophia Antipolis, PhD in molecular pharmacology Master in Molecular Pharmacology & Molecular biology, BS in Biochemistry.
Career: Georges GAUDRIAULT, PhD, has nearly 20 years of experience in drug research and development. He then masters every step along the value chain, including regulatory aspects and market access. Before joining DEINOVE, he held for nine years the position of Chief scientific officer at MedinCell, a biopharmaceutical company specializing in long-acting drug delivery.
He was also a Scientific director at ObeTherapy - a biotechnology start-up specializing in the discovery and development of therapies in the fields of obesity, hypercholesterolemia, and type II diabetes - and contributed to research at the Institut Curie.
In addition, Georges GAUDRIAULT has solid experience in the United States, having spent several years as a research scientist at the prestigious Salk Institute.
He is the author of several patents and numerous publications.
Coralie MARTIN, Head of Communications and Investor Relations
Education: Engineer inBiochemistry INSA Toulouse, Master in Business IAE Lyon
Career: Coralie MARTIN undertook several missions as research engineer at the University UQAM (Canada) and Sanofi-Aventis (Toulouse). She then specialized in communication and marketing of pharmaceutical products, with several missions for Laboratoires Pierre Fabre and more recently for bioMérieux Chile. She has strong skills in biochemistry and international experience.